+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

United Kingdom (UK) Biotechnology Market Summary, Competitive Analysis and Forecast to 2028

  • PDF Icon

    Report

  • 44 Pages
  • February 2024
  • Region: United Kingdom
  • MarketLine
  • ID: 5694017
Biotechnology in the United Kingdom industry profile provides top-line qualitative and quantitative summary information including: market size (value 2018-23, and forecast to 2028). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Highlights

  • The biotechnology market encompasses a broad range of technologies, products, and services that utilize biological systems, organisms, or derivatives to develop or modify processes or products for specific applications.
  • The UK biotechnology market recorded revenues of $145.3 billion in 2023, representing a compound annual growth rate (CAGR) of 7% between 2018 and 2023.
  • The medical/healthcare segment accounted for the market's largest proportion in 2023, with total revenues of $101.6 billion, equivalent to 70% of the market's overall value.
  • The UK biotechnology market is experiencing growth due to innovation and the potential for significant therapeutic developments. The UK biotech industry continues to grow significantly as venture finance, private equity, and initial public offerings (IPOs) support R&D and expansion. For instance, the British Science, Research and Innovation Ministry has announced a $2.5 billion 10-year plan to promote engineering biology, aiming to harness the potential of cellular agriculture, genomic techniques, and medicinal advancements.

Scope

  • Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the biotechnology market in the United Kingdom
  • Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the biotechnology market in the United Kingdom
  • Leading company profiles reveal details of key biotechnology market players’ global operations and financial performance
  • Add weight to presentations and pitches by understanding the future growth prospects of the United Kingdom biotechnology market with five year forecasts

Reasons to Buy

  • What was the size of the United Kingdom biotechnology market by value in 2023?
  • What will be the size of the United Kingdom biotechnology market in 2028?
  • What factors are affecting the strength of competition in the United Kingdom biotechnology market?
  • How has the market performed over the last five years?
  • What are the main segments that make up the United Kingdom's biotechnology market?

Table of Contents

1 Executive Summary
1.1. Market value
1.2. Market value forecast
1.3. Category segmentation
1.4. Geography segmentation
1.5. Market rivalry
1.6. Competitive landscape
2 Market Overview
2.1. Market definition
2.2. Market analysis
3 Market Data
3.1. Market value
4 Market Segmentation
4.1. Category segmentation
4.2. Geography segmentation
5 Market Outlook
5.1. Market value forecast
6 Five Forces Analysis
6.1. Summary
6.2. Buyer power
6.3. Supplier power
6.4. New entrants
6.5. Threat of substitutes
6.6. Degree of rivalry
7 Competitive Landscape
7.1. Who are the leading players?
7.2. What strategies do the leading players follow?
7.3. What is the rationale behind recent M&A activity?
8 Company Profiles
8.1. AstraZeneca PLC
8.2. Novartis AG
8.3. GSK plc.
8.4. GE HealthCare Technologies Inc.
9 Macroeconomic Indicators
9.1. Country data
10 Appendix
10.1. Methodology
10.2. Industry associations
10.3. Related Research
10.4. About the Publisher
List of Tables
Table 1: United Kingdom biotechnology industry value: $ million, 2018-23
Table 2: United Kingdom biotechnology industry category segmentation: % share, by value, 2018-2023
Table 3: United Kingdom biotechnology industry category segmentation: $ million, 2018-2023
Table 4: United Kingdom biotechnology industry geography segmentation: $ million, 2023
Table 5: United Kingdom biotechnology industry value forecast: $ million, 2023-28
Table 6: AstraZeneca PLC: key facts
Table 7: AstraZeneca PLC: Annual Financial Ratios
Table 8: AstraZeneca PLC: Key Employees
Table 9: AstraZeneca PLC: Key Employees Continued
Table 10: Novartis AG: key facts
Table 11: Novartis AG: Annual Financial Ratios
Table 12: Novartis AG: Key Employees
Table 13: GSK plc.: key facts
Table 14: GSK plc.: Annual Financial Ratios
Table 15: GSK plc.: Key Employees
Table 16: GSK plc.: Key Employees Continued
Table 17: GE HealthCare Technologies Inc.: key facts
Table 18: GE HealthCare Technologies Inc.: Key Employees
Table 19: United Kingdom size of population (million), 2019-23
Table 20: United Kingdom gdp (constant 2005 prices, $ billion), 2019-23
Table 21: United Kingdom gdp (current prices, $ billion), 2019-23
Table 22: United Kingdom inflation, 2019-23
Table 23: United Kingdom consumer price index (absolute), 2019-23
Table 24: United Kingdom exchange rate, 2019-23
List of Figures
Figure 1: United Kingdom biotechnology industry value: $ million, 2018-23
Figure 2: United Kingdom biotechnology industry category segmentation: $ million, 2018-2023
Figure 3: United Kingdom biotechnology industry geography segmentation: % share, by value, 2023
Figure 4: United Kingdom biotechnology industry value forecast: $ million, 2023-28
Figure 5: Forces driving competition in the biotechnology industry in the United Kingdom, 2023
Figure 6: Drivers of buyer power in the biotechnology industry in the United Kingdom, 2023
Figure 7: Drivers of supplier power in the biotechnology industry in the United Kingdom, 2023
Figure 8: Factors influencing the likelihood of new entrants in the biotechnology industry in the United Kingdom, 2023
Figure 9: Factors influencing the threat of substitutes in the biotechnology industry in the United Kingdom, 2023
Figure 10: Drivers of degree of rivalry in the biotechnology industry in the United Kingdom, 2023

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AstraZeneca PLC
  • Novartis AG
  • GSK plc.
  • GE HealthCare Technologies Inc.